Optic IconOptic Logo
|
SearchCollectionsBenchmarks

zilurgisertib

1 abstract

Abstract
Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).
Org: Incyte, Incyte Biosciences International, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy,